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Abstract 
Organophosphates such as nerve agents have been used on several occasions in 
the past to inflict harm upon military and civilian populations in various parts of the 
world.  The threat of these chemicals use against the military and civilians continues 
today, and the suggested treatment guidelines available may be ineffective or possibly 
cause harm.  The guidelines investigated during the research presented here all included 
the use of three antidotes, atropine, oxime, and diazepam.  Controversy exists over the 
use of oxime to treat organophosphate poisoning and various studies have concluded that 
they may be harmful.  Both atropine and oxime are issued to military members for self-
treatment following nerve agent exposure.  Additionally, civilian medical facilities have 
access to both antidotes to treat patients exposed to nerve agents or organophosphate-
based pesticides.  The research presented here used a physiologically-based 
pharmacokinetic model to determine an optimal treatment strategy for exposures to 
organophosphates.  Results from the model suggest that the treatment of organophosphate 
poisoning according to current guidance has the potential to increase the severity of 
symptoms that a patient is experiencing.  The results presented indicate that oxime use is 
beneficial when the patient has been exposed to a weak organophosphate such as a 
pesticide, but not as prescribed in current guidance.  Additionally, results indicate that in 
scenarios involving strong organophosphates such as nerve agents, oxime use is 
ineffective and has the potential to increase the severity of symptoms.  Finally, the model 
was used to determine an optimal dosing strategy for treatment of organophosphate 
poisoning that varies significantly from the guidance currently available.
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DEVELOPMENT OF OPTIMIZED GUIDELINES FOR THERAPEUTIC 
STRATEGIES FOR ORGANOPHOSPHATE POISONING 
 
I. Introduction 
Background 
 The ever present threat of organophosphate and nerve agent use as weapons in 
military conflicts or acts of terrorism requires an effective therapeutic strategy for 
ushering exposed populations back to health.  Organophosphates, esters of phosphoric 
acid, have various uses including insecticides, flame retardants, plasticizers, emulsifiers, 
and additives to lubricating oil (Szinicz, 2005; Cannard, 2006).  Organophosphorous 
compounds also have use in veterinary and human medicine to treat against ticks, fleas, 
and lice (Karalliedde, 1999).  Globally, approximately 3 million people are poisoned and 
260,000 die annually from overexposure to organophosphates (Karalliedde, 1999; 
Aurbek, 2009).  Organophosphates are a threat to military and civilian personnel in a 
terrorist attack, and an occupational hazard to workers exposed to organophosphate-based 
insecticides (Kassa, 2002). 
 Historically, organophosphates were first synthesized in the 19th century in 
France, but the development of these compounds increased significantly in Germany in 
the 1930s and during World War II (Szinicz, 2005).  This work was initially intended to 
develop new insecticides, but due to these chemical’s high toxicity, quickly drew the 
attention of the German Ministry of War (Szinicz, 2005).  The nerve agents, sarin, tabun, 
and soman were developed from this research (Szinicz, 2005).  In response, the United 
States, Great Britain, and Soviet Union, began researching nerve agents of their own 
  
2 
 
(Szinicz, 2005).  This research led to the joint development of VX by the United States 
and Great Britain in the 1950s (Szinicz, 2005).  Despite the high level of research and 
production of nerve agents during the 1940s and 1950s, these chemicals were not used in 
warfare or terrorism until the 1980s by Iraq, and in the 1990s by a Japanese religious cult, 
Aum Shinrikyo (Cannard, 2006). 
Organophosphates produce their deleterious effects by inhibiting the enzyme 
acetylcholinesterase (AChE), which is responsible for breaking down the 
neurotransmitter acetylcholine (Cannard, 2006).  At homeostasis, once acetylcholine is 
released in the synapse, it is broken down into choline and acetic acid by 
acetylcholinesterase (Cannard, 2006).  When organophosphates are present, they bind 
with the acetylcholinesterase, preventing the breakdown of acetylcholine (Cannard, 
2006).  As a result, acetylcholine is able to continuously react with its receptor, causing 
the repeated stimulation of the cell (Cannard, 2006).  Depending on the level of exposure, 
symptoms of organophosphate exposures may include miosis, blurred vision, headache, 
bronchoconstriction, bronchorrhea, rhinorrhea, nausea, vomiting, diarrhea, paralysis, 
mental instability, unconciousness, seizures, and apnea (Cannard, 2006).  Respiratory 
failure is the leading cause of death from overexposure to organophosphates (Cannard, 
2006). 
The three primary antidotes for organophosphate poisoning are anticholinergics, 
oximes, and anticonvulsants (Cannard, 2006).  The predominant anticholinergic used is 
atropine, which blocks acetylcholine from binding to muscarinic receptors, but is not 
effective at nicotinic receptors (Cannard, 2006).  As a result, atropine is effective at 
stopping the symptoms of excessive secretions and smooth muscle stimulation, but does 
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not treat the effects of paralysis (Cannard, 2006).  Unlike atropine, oximes help treat 
weakness and paralysis (Cannard, 2006).  Oximes break the bond between 
organophosphates and acetylcholinesterase, enabling the acetylcholinesterase to resume 
its function of breaking down acetylcholine (Cannard, 2006).  Seizures and convulsions 
are possible with exposures to high doses (Cannard, 2006).  The anticonvulsant typically 
used for the treatment of seizures is diazepam (Cannard, 2006).  Most armed forces use 
autoinjectors with atropine and an oxime for treating exposures to organophosphates 
(Szinicz, 2005).  The U.S. military specifically uses atropine ant pralidoxime chloride (2-
PAM Cl) in the autoinjectors it issues to its personnel (USAMRICD, 2007).  
Several government agencies, to include the Centers for Disease Control and 
Prevention (CDC), the New York Department of Health (NYDH), and the U.S. Army 
Medical Research Institute of Chemical Defense (USAMRICD), have guidelines for 
administering antidotes to patients exposed to organophosphates.  Each guideline 
recommends the use of atropine, oxime, and an anticonvulsant, but each varies in the 
amount of each dose as well as the timing of subsequent doses (CDC, 2008; NYDH, 
2005; USAMRICD, 2007).  Due to anticonvulsants treating patients by a different 
mechanism from that of atropine and oxime, anticonvulsants were not evaluated during 
the course of this research. 
Many researchers have questioned the effectiveness of oxime treatment and have 
conducted studies to determine if they are effective or possibly harmful (Eddleston and 
others, 2009).  Those that favor oxime treatment state that these studies have not used an 
adequate dose of oxime (Eddleston and others, 2009).  The doubt raised in these studies 
needs to be investigated and a more optimal antidote dosing strategy needs to be 
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developed.  A method to conduct such research that is cost-effective, less time 
consuming, and without extensive animal testing is by the use of a physiologically-based 
pharmacokinetic (PBPK) model (Andersen, 2003). 
PBPK models use data derived from in vitro and in vivo testing to predict how a 
chemical will behave in a variety of scenarios (Andersen, 2003).  The model uses 
compartments to describe different tissue groups that have similar pharmacokinetic 
properties (Andersen, 2003).  Mass balance equations are written for each tissue and the 
software derives the differential equation to predict the concentration of the chemical 
over time (Andersen, 2003).  The application of PBPK modeling with organophosphates 
has been investigated by several researchers and the results have shown that this method 
is promising in predicting how organophosphates behave in humans. 
The varying treatment guidelines, as well as the questionable effectiveness of 
oxime treatment, led to the research conducted by Seaman (Seaman, 2008).  Seaman 
developed a PBPK model to predict the concentration of organophosphates, atropine, 
oxime, acetylcholine, acetylcholinesterase, and other biological chemicals in body tissues 
over time (Seaman, 2008).  Using this model, he was able to simulate various exposure 
conditions and treatment strategies (Seaman, 2008).  Seaman’s model was based on 
PBPK models developed previously to describe organophosphate exposure and 
acetylcholine inhibition.  Among these include the models developed by Gearhart and 
others for diisopropylfluorophosphate (DFP) and parathion (Gearhart and others, 1994), 
Timchalk and others for chlorpyrifos (Timchalk and others, 2002), and Gentry and others 
for parathion (Gentry and others, 2002).  In addition to the model developed by Seaman, 
other models have been developed to analyze the effectiveness of antidotes in 
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organophosphate poisoning.  Multiple models were developed by Worek and others to 
demonstrate the effectiveness of oximes in nerve agent poisoning (Worek and others, 
2005) and later expanded that model to incorporate the nerve agent pretreatment by 
carbamates such as pyridostigmine (Worek and others, 2007). 
Pharmacokinetic data for organophosphates for humans is limited.  Human 
studies with organophosphates, specifically nerve agents, would be unethical due to the 
high toxicity of most organophosphates.  Real world exposures to include occupational 
exposure to insecticides and the use of nerve agents in warfare and terrorism have 
provided the limited human data available.  These real world exposures include the use of 
the nerve agents sarin and tabun by Iraq against Iran in the mid-1980s, and their later use 
of sarin against the Kurds in 1988 (Szinicz, 2005; Cannard, 2006).  Additionally, the 
potential for terrorist use of nerve agents exists as exhibited by a Japanese religious cult, 
Aum Shinrikyo, that used sarin on two occasions in Matsumoto and Tokyo in the mid-
1990s (Szinicz, 2005; Cannard, 2006). 
It appears that the possibility of the use of organophosphates or nerve agents in 
warfare has declined, but the potential still exists for its use by terrorist organizations 
against both military and civilian populations (Szinicz and others, 2007).  Since it appears 
that a greater percentage of the world’s population is at risk to exposure from 
organophosphates, there is a definite need for research into suitable antidotes and their 
application. 
Controversy exists over the dosing and timing of atropine and pralidoxime 
treatment, and the use of pralidoxime for organophosphate exposure at all has been 
questioned (Karalliedde, 1999).  Oxime treatment has been observed to be ineffective 
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under several situations: when the bond between the organophosphate and 
acetylcholinesterase has become irreversible, when acetylcholinesterase is bound by 
organophosphates in the system faster than it is reactivated, or when oxime treatment is 
stopped too soon (Szinicz, 2007).  Additionally, due to the low incident rate of 
organophosphate poisoning, little research into developing new treatment methods or 
validating current methods has been performed (Szinicz, 2007).  Due to the apparent 
controversy of oxime efficacy, additional research needs to be performed to determine 
appropriate dosing, timing, or if they should be used at all.  This controversy and the 
variations in the recommendations for antidote dosing and timing from different agencies 
is the basis for this research. 
 
Research objectives 
1. Validate the physiologically-based pharmacokinetic (PBPK) model produced by 
Seaman and modify it as necessary to perform the simulations required to 
complete this research 
2. Analyze the current therapeutic strategies using the validated PBPK model in 
various exposure situations to determine if they are effective or cause harm 
3. Develop a set of guidelines that provides an optimal dosing and timing strategy 
for various exposure situations to include military, terrorist, or occupational 
exposures to reduce death among initial survivors and hasten full recovery. 
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II. Literature Review 
History of organophosphates 
Organophosphates are synthetically derived, and the origins of the first such 
compound can be traced back to the mid-1800s in France (Szinicz, 2005).  The synthesis 
of organophosphate insecticides began in the 1930s by German chemist Gerhard 
Schrader (Szinicz, 2005; Cannard, 2006).  Schrader’s work led to the development of 
over 2,000 organophosphate compounds, including tabun in 1936 and sarin in 1937 
(Szinicz, 2005).  Schrader’s work drew attention from the German Ministry of War, and 
approximately 200 of his compounds were recognized as potential chemical warfare 
agents including tabun, sarin, and soman (Szinicz, 2005; Cannard, 2006).  
 Germany began full production of tabun, sarin, and soman, in the 1940s (Szinicz, 
2005).  In response to the German research into nerve agents, research began in the 
United States, Great Britain, France, and the Soviet Union (Szinicz, 2005).  Chemical 
warfare research following World War II focused on the development of nerve agents 
(Szinicz, 2005).  Sarin was the nerve agent of choice in the United States and the Soviet 
Union and was stockpiled by both countries following World War II (Szinicz, 2005).  
Although Germany developed and possessed large quantities of nerve agents, they did 
not use them (Cannard, 2006).  During the 1950s, insecticide companies also became 
interested in the potential of organophosphates (Szinicz, 2005).  Also in the 1950s, joint 
research between Great Britain and the United States led to the development of VX, and 
it went into production in the United States in 1961 (Szinicz, 2005).   
Nerve agents, specifically sarin and tabun, were used by Iraq during the Iraq-Iran 
war in the 1980s (Szinicz, 2005; Cannard, 2006).  Iraq again used sarin against the Kurds 
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in 1988 (Szinicz, 2005; Cannard, 2006).  A Japanese religious cult, Aum Shinrikyo, used 
sarin in multiple attacks in Matsumoto and Tokyo in 1994 and 1995, respectively 
(Szinicz, 2005; Cannard, 2006).  In the Tokyo subway attack, only 12 of the 
approximately 1,000 exposed died, but the sarin used was only 30% pure and not 
optimally dispersed (Cannard, 2006).  These real world uses have helped determine 
which antidotes are the most effective (Cannard, 2006). 
 
Physiology of organophosphate poisoning  
Organophosphates are esters of phosphoric acid with the most toxic being used as 
nerve agents in chemical warfare (Karalliedde, 1999).  Organophosphates have a 
phosphorus atom at their center that is bound to two alkyl groups, a leaving group, and a 
double bond with oxygen (Cannard, 2006).  The leaving group breaks off when the 
organophosphate bonds with an acetylcholinesterase (Cannard, 2006).  Organophosphates 
are liquids at room temperature, but can be volatilized by a sprayer or explosion 
(USAMRICD, 2007).  Most nerve agents are not persistent in the environment and fall 
below lethal concentrations fairly rapidly (Cannard, 2006).  VX is not as volatile as other 
organophosphates, is more persistent in the environment, and poses a greater dermal 
hazard than other nerve agents (Cannard, 2006). 
Organophosphates cause deleterious effects in the central nervous system, 
cardiovascular system, metabolic system, endocrine system, reproduction system, and the 
neuromuscular junction (Karalliedde, 1999).  The probable route of exposure for an 
organophosphate is by inhalation, but can also occur by digestion or absorption through 
contact with the eye, skin, or mucous membranes (Cannard, 2006).  Organophosphates 
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exhibit their toxic effects by binding with acetylcholinesterase, which inhibits the 
breakdown of acetylcholine (Aurbek and others, 2009).  After a period of time, the bond 
between the organophosphate and acetylcholinesterase becomes permanent and is 
referred to as aging (Cannard, 2006).  Other cholinesterase inhibitors include carbamates 
and other organophosphorus compounds (Cannard, 2006).  Pyridostigmine bromide, a 
pretreatment for a potential soman exposure, is a member of the carbamate family 
(Cannard, 2006).  The bind between a carbamate and acetylcholinesterase is reversible 
and breaks down naturally within one to six hours (Cannard, 2006).  Once aging has 
occurred, acetylcholinesterase levels only recover through the production of new 
acetylcholinesterase, a process that may take weeks to months to occur (Cannard, 2006).  
In addition to acetylcholinesterase, human tissue also contains butyrylcholinesterase 
(BuChE) and carboxylesterase (Cannard, 2006).  Organophosphates also bind to these 
two enzymes, but to differing affinity than acetylcholinesterase (Cannard, 2006).  
Additionally, the physiological effects of organophosphates binding to these two 
enzymes do not seem to be as critical as the binding to acetylcholinesterase (Cannard, 
2006). 
Physiologically, the function of butyrylcholinesterase has yet to be determined, 
but it has shown the ability to act as a natural defense mechanism against 
organophosphate poisoning (Bartling and others, 2007).  The liver produces 
butyrylcholinesterase and releases it into the blood stream (Aurbek and others, 2009). 
The human body contains two types of cholinergic receptors, muscarinic and 
nicotinic (Cannard, 2006).  Muscarinic receptors are responsible for the stimulation of 
smooth muscles and exocrine glands (Cannard, 2006).  They can also be found in the 
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central nervous system (Cannard, 2006).  Muscarinic receptors stimulate lacrimal, nasal, 
salivary, and bronchial glands, intraocular and bronchial muscles, the heart, and bladder 
(Cannard, 2006).  Symptoms associated with muscarinic receptor overstimulation are 
miosis, blurred vision, eye pain, headache, rhinorrhea, salivation, bronchorrhea, 
hypotension, nausea, vomiting, diarrhea, and bowel or urinary incontinence (Cannard, 
2006).  Nicotinic receptors are located in the neuromuscular junctions of somatic muscles 
as well as the autonomic ganglia (Cannard, 2006).  Overstimulation of nicotinic receptors 
causes the repeated stimulation of individual muscle fibers, preventing the coordinated 
contraction of the muscles (Cannard, 2006).  With the continual stimulation of the muscle 
fibers, fatigue and paralysis can quickly set in (Cannard, 2006).  Muscarinic and nicotinic 
receptors are both found in the central nervous system and excessive stimulation may 
cause behavioral changes, coma, seizures, or central apnea (Cannard, 2006). 
Onset of symptoms can present within a few seconds when exposed to a high dose 
or if the exposure is by inhalation (Cannard, 2006).  Symptoms associated with exposure 
by inhalation typically peak 15 to 30 minutes following exposure (Cannard, 2006).  
Inhalation of organophosphates is typically the most lethal route of exposure due to the 
distribution systemically through the circulatory system and death can occur within 
seconds (Cannard, 2006).  Generally, survival rates are high if the patient withstands the 
first 30 minutes following exposure (Cannard, 2006).  Symptoms associated with a 
dermal exposure may be delayed up to 18 hours (Cannard, 2006).  Consequently, without 
an accurate exposure history from the patient, dermal exposures may not be accurately 
diagnosed (Cannard, 2006).  Dermal exposures will also likely exhibit symptoms 
localized to the area of exposure (Cannard, 2006). 
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During organophosphate poisoning, the acetylcholinesterase enzyme is 
phosphorylated, producing an organophosphate-acetylcholinesterase complex 
(Thiermann and others, 1999).  This complex exhibits the potential to release the 
acetylcholinesterase naturally without the use of any medical treatment (Thiermann and 
others, 1999).  The process of aging occurs when the organophosphate-
acetylcholinesterase complex loses a hydroxyl group, preventing the complex from 
breaking down either naturally or with medical treatment (Thiermann and others, 1999).  
Oxime-induced degradation of the organophosphate-acetylcholinesterase complex occurs 
in a two-step process; the first step produces a phosphorylenzyme-oxime complex that is 
followed by the second step of releasing acetylcholinesterase (Thiermann and others, 
1999).  The potential exists for oxime treatment to produce phosphorylated oximes, 
which are cholinesterase inhibitors as well (Karalliedde, 1999). 
The level of acetylcholinesterase activity shows a good correlation with the level 
of symptoms exhibited by the patient (Ashani and Pistinner, 2004).  An acetylcholine 
level of 35% of the basal level would likely cause symptoms associated with 
organophosphate poisoning, and an acetylcholinesterase level of 10% of the basal level is 
required to maintain physiological responses in the brain and diaphragm (Ashani and 
Pistinner, 2004). 
 
Antidotes 
 The physiological effects of organophosphate exposure were discovered by 
Germany, Great Britain, and the United States during World War II (Szinicz, 2005).  The 
Germans discovered that atropine was an effective antidote to organophosphate exposure 
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and used it to treat exposures during research and production during World War II 
(Szinicz, 2005).  The United States Army began using an autoinjector with atropine in the 
1950s (Szinicz, 2005).  Most armed forces today use autoinjectors with atropine and an 
oxime (Szinicz, 2005).  A patient’s recovery from organophosphate exposure requires 
treatment within a few hours due to the bond between organophosphates and 
acetylcholinesterase becoming irreversible (Cannard, 2006).  Early diagnosis of 
organophosphate poisoning is critical to the survival of the patient; however, due to the 
rarity of organophosphate poisoning, it is often misdiagnosed (Cannard, 2006).   
Atropine effectively treats organophosphate poisoning by competing with 
abundant acetylcholine at the muscarinic receptors, but has not shown to be effective at 
nicotinic receptors such as at the neuromuscular junction (Karalliedde, 1999).  Atropine 
treatment does not reverse miosis, therefore the size of the pupil should not be used as a 
method to determine efficacy of treatment (Cannard, 2006).  Atropine is effective at 
crossing the blood-brain barrier and acts to counteract the effects of excess acetylcholine 
in the central nervous system (Karalliedde, 1999).  Atropine therapy has proven to be a 
successful antidote and has reduced the mortality from exposure to organophosphates 
(Karalliedde, 1999).  The traditional initial dose of atropine is 2–6 mg by either 
intravenous or intramuscular injection, although intravenous is preferred if it is available 
(Cannard, 2006).  Atropine itself is toxic and personnel that receive small amounts, 2 mg, 
without organophosphate poisoning may exhibit a reduction in secretions, sedation, a 
reduction in digestive motility, and tachycardia (USAMRICD, 2007).  Larger doses of 
atropine on the order of 10 mg, may produce delirium in patients (USAMRICD, 2007). 
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Once the bond between organophosphate and acetylcholinesterase matures, 
oximes lose their effectiveness and are unable to break the bond (Cannard, 2006).  
Acetylcholinesterase recovers fairly slowly in the body at a rate of approximately 1% per 
day (Karalliedde, 1999).  Each organophosphate ages at different rates; soman has an 
aging half time of two to six minutes while other nerve agents have aging half times from 
five to 48 hours (Cannard, 2006).  Due to the rapid aging of soman, oxime treatment will 
likely be ineffective since the bonds will be irreversibly bound before medical treatment 
can commence (Cannard, 2006).  Oximes typically do not affect symptoms associated 
with muscarinic receptors, thus oxime treatment is likely not necessary with mild 
exposures (Cannard, 2006).  The oxime used in the United States is pralidoxime chloride, 
or 2-PAM Cl (2-pyridinealdoxime methiodide chloride) (Cannard, 2006). 
A potential side-effect of oxime treatment is hypertension (Cannard, 2006).  
Pralidoxime treatment can produce deleterious effects to include drowsiness, headache, 
vision problems, nausea, dizziness, tachycardia, hyperventilation, and muscular weakness 
(Kassa, 2002).  The most common cause of death in oxime poisoning is respiratory 
paralysis (Kassa, 2002). 
Based on early data, an oxime plasma concentration of 4 μg/mL was determined 
the amount necessary to reverse organophosphate symptoms, but later data has raised 
doubt upon this value (Kassa, 2002).  Several factors are responsible for the efficacy of 
oxime therapy, including the specific organophosphate, the route of exposure, and the 
route and timing of oxime treatment (Kassa, 2002).  Pralidoxime appears to be much 
more effective against insecticides than nerve agents (Kassa, 2002).  Pralidoxime is not 
considered to be effective enough against nerve agents, but newly developed oximes, HI-
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6 and HLö-7, have demonstrated better ability to protect against nerve agents and 
increase survivability (Kassa, 2002).  Pralidoxime is stable as an aqueous solution, 
enabling it be stored in solution; HI-6 and HLö-7 are not stable in water and must be 
stored as a powder until needed (Kassa, 2002).  The oximes pralidoxime, obidoxime, and 
HI-6, are available as an auto-injector for use in the field (Kassa, 2002). 
There is a lack of evidence that supports how effective the current treatment 
methods are for organophosphate poisoning (Szinicz, 2007).  Due to the low incident rate 
of organophosphate poisoning, little research has gone into developing new treatment 
methods or verifying how effective current treatment methods are (Szinicz, 2007).  In 
vitro studies have demonstrated the potential for oximes to be an effective treatment for 
organophosphate poisoning, but in actual practice with exposed victims, oximes have 
been less effective or even harmful (Szinicz, 2007).  At large doses, pralidoxime itself 
has been shown to inhibit acetylcholinesterase (Karalliedde, 1999).  The use of an oxime 
without the use of atropine has shown minimum effectiveness (Szinicz, 2007).  The 
blood-brain barrier hinders the passage of oximes and limits their effectiveness in the 
brain (Karalliedde, 1999).  Pralidoxime is most effective at the neuromuscular junction, 
but is not effective at muscarinic receptors (Karalliedde, 1999).  Additionally, the 
effectiveness of oximes may be dependent on the dose of atropine that has been 
administered (Szinicz, 2007). 
The reactivation of acetylcholinesterase is dependent on the efficacy of the oxime 
treatment, the rate the bond between acetylcholinesterase and organophosphate ages, and 
the rate of natural reversal of the bonding (Szinicz, 2007).  Oxime effectiveness can be 
evaluated by how well the patient recovers their neuromuscular functions (Szinicz, 2007).  
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Acetylcholinesterase can be inhibited by both persistent organophosphates remaining in 
the system, or by organophosphates that are freed when oximes break the 
acetylcholinesterase-organophosphate bond (Szinicz, 2007).  The dose required for an 
oxime to produce beneficial results is dependent on the type of organophosphate 
(Thiermann and others, 1999).  The rate of reactivation of the enzymes, 
acetylcholinesterase and butyrylcholinesterase, is dependent on the type of enzyme, the 
oxime used, and the organophosphate to which exposed (Bartling and others, 2007). 
The use of clonidine and fluoride treatment for organophosphate poisoning has 
provided promising results and further research into their applicability is required 
(Karalliedde, 1999).  According to Karalliedde, the therapeutic methods in place have not 
produced acceptable results and need to be revisited (Karalliedde, 1999). 
In research performed by Aurbek and others, it was determined that oxime 
treatment was less effective in reactivating butyrylcholinesterase than 
acetylcholinesterase (Aurbek and others, 2009).  The researchers were able to show that 
organophosphates reacted with acetylcholinesterase and butyrylcholinesterase at similar 
rates, and butyrylcholinesterase is an effective defense against organophosphate 
poisoning (Aurbek and others, 2009).   
 
Current therapeutic recommendations 
 Various organizations, including the World Health Organization (WHO), the 
Centers for Disease Control and Prevention (CDC), the U.S. Army Medical Research 
Institute of Chemical Defense (USAMRICD), and the New York Department of Health 
(NYDH), have therapeutic guidelines for the treatment of organophosphate exposures.  
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Each agency’s guideline varies in the amount of each dose and the timing of dosing 
(Cannard, 2006). 
 The CDC provides recommendations for the administering of nerve agent 
antidotes to emergency responders and to hospital medical staff (CDC, 2010).  
Emergency responders are advised to administer 2 to 4 mg of atropine and 600 mg of 
pralidoxime intramuscularly for mild to moderate symptoms (CDC, 2010).  For severe 
symptoms, 6 mg of atropine and 1,800 mg of pralidoxime intramuscularly are 
recommended (CDC, 2010).  The CDC considers mild to moderate symptoms to include 
localized sweating, muscle twitching, nausea, vomiting, muscle weakness, and dyspnea 
(CDC, 2010).  Unconsciousness, convulsions, apnea, and paralysis are classified as 
severe symptoms by the CDC (CDC, 2010).  A repeat dose of 2 mg of atropine is 
recommended every 5 to 10 minutes until breathing becomes normal and reduction in 
secretions have occurred (CDC, 2010).  The CDC does not provide guidance for repeat 
doses of pralidoxime (CDC, 2010). 
 The CDC’s recommendations for emergency department staff vary slightly from 
their recommendations in the field.  The recommendation for atropine dosing and timing 
are identical to the recommendation to emergency responders (CDC, 2010).  Pralidoxime 
therapy does vary with a recommended dose of 15 mg/kg (approximately 1,000 mg for 
adults) given slowly intravenously (CDC, 2010).  This dose does not vary, regardless of 
the severity of symptoms (CDC, 2010).  The CDC does not provide guidance to hospital 
staff on subsequent dosing of pralidoxime (CDC, 2010). 
 The NYDH has also developed a set of recommendations for emergency 
responders and emergency department personnel.  For mild to moderate symptoms, 
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which include sweating, muscle twitching, nausea, vomiting, weakness, and shortness of 
breath, the NYDH recommends an initial atropine dose of 2 to 4 mg intramuscularly or 
intravenously and 600 mg of pralidoxime chloride intramuscularly or a slow infusion of 
25 mg/kg intravenously (NYDH, 2005).  NYDH recommends repeating atropine every 2 
to 5 minutes until secretions and breathing have returned to close to normal (NYDH, 
2005).  An additional pralidoxime dose is recommended at 30 to 60 minutes, then hourly 
for 1 or 2 additional doses (NYDH, 2005).  The quantity for repeat doses of neither 
atropine nor pralidoxime are clearly identified (NYDH, 2005). 
 The NYDH provides an additional set of measures for severe exposures, which 
according to the NYDH include unconsciousness, seizures, apnea, and paralysis (NYDH, 
2005).  The recommendations for severe exposures are 6 mg of atropine intramuscularly 
and either 1800 mg of pralidoxime intramuscularly or 50 mg/kg by slow intravenous 
infusion (NYDH, 2005).  Additional dosing follows the same recommendations as mild 
and moderate exposures (NYDH, 2005). 
USAMRICD provides treatment recommendations to military personnel in the 
field and to medical personnel in field hospitals (USAMRICD, 2007).  USAMRICD 
recommends a symptoms-based treatment strategy (USAMRICD, 2007).  Military 
personnel in the field are issued three MARK I Kits (USAMRICD, 2007).  Each kit 
contains two auto-injectors, one with 2 mg of atropine and one with 600 mg of 
pralidoxime chloride (USAMRICD, 2007).  A replacement for the MARK I Kit has been 
developed in the form of the Antidote Treatment – Nerve Agent, Auto-injector (ATNAA) 
(FDA, 2006).  The ATNAA contains 2.1 mg of atropine and 600 mg of pralidoxime in 
separate chambers of a single auto-injector that sequentially injects the antidotes through 
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a single needle (FDA, 2002).  For military personnel in the field, their guidance 
recommends the self-administration of one MARK I Kit if the individual is experiencing 
effects from nerve agent exposure (USAMRICD, 2007).  An additional MARK I Kit is 
recommended if there is no improvement within 10 minutes (USAMRICD, 2007).  For 
severe exposures where the individual is unable to self-administer antidote, a bystander 
should administer all three MARK I Kits to the exposed individual and any additional 
treatment would not be administered until the individual arrives at a medical facility 
(USAMRICD, 2007).   
Medical personnel are advised to administer one MARK I Kit if the casualty is 
experiencing miosis and severe rhinorrhea (USAMRICD, 2007).  One or two doses are 
recommended for mild to moderate dyspnea (USAMRICD, 2007).  For severe exposures, 
USAMRICD recommends the immediate administering of three MARK I Kits 
(USAMRICD, 2007).  Subsequent dosing of atropine is recommended based on the level 
of secretions and necessity of assisted ventilation (USAMRICD, 2007).  A 2 mg dose 
repeated every three to five minutes is recommended by the intravenous (IV) route until 
ventilation is no longer required (USAMRICD, 2007).  USAMRICD recommends oxime 
therapy to continue for two to three additional doses every hour (USAMRICD, 2007).  
They recommend that 1 gram of oxime be administered via IV over a 20 to 30-minute 
period (USAMRICD, 2007).  In lieu of IV availability, USAMRICD recommends three 
pralidoxime auto-injectors (USAMRICD, 2007). 
The WHO recommends an oxime treatment strategy with an initial dose of 30 
mg/kg (approximately 2,000 mg for an adult) and subsequent doses of 8 mg/kg 
(approximately 500 mg for an adult) every hour (Eddleston and others, 2009).  The 
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dosing recommendations for antidote treatment from the CDC, NYDH, and USAMRICD 
are shown in Table 1 and Table 2. 
Table 1.  Antidote recommendations for mild/moderate symptoms 
  CDC 
(field) 
CDC 
(hospital) 
NYDH USAMRICD 
(field) 
USAMRICD 
(hospital) 
Atropine Initial Dose 2 – 4 mg 2- 4 mg 2 – 4 mg 2 mg 2 - 4 mg 
 Repeat Dose 2 mg 2 mg Not 
specified 
2 mg No 
instructions 
 Repeat Interval 5 – 10 min 5 – 10 min 2 – 5 min 10 min No 
instructions 
Pralidoxime Initial Dose 600 mg 1000 mg 600 mg 600 mg 600 – 1200 mg 
 Repeat Dose No 
instructions 
No 
instructions 
Not 
specified 
600 mg No 
instructions 
 Repeat Interval No 
instructions 
No 
instructions 
30 – 60 min, 
then hourly 
10 min No 
instructions 
(CDC, 2010; NYDH, 2005; USAMRICD, 2007)  
 
Table 2.  Antidote recommendations for severe symptoms 
  CDC 
(field) 
CDC 
(hospital) 
NYDH USAMRICD 
(field) 
USAMRICD 
(hospital) 
Atropine Initial Dose 6 mg 6 mg 6 mg 6 mg 6 mg 
 Repeat Dose 2 mg 2 mg Not 
specified 
Not applicable, 
only 6 mg 
carried in field 
2 mg 
 Repeat Interval 5 – 10 min 5 – 10 mg 2 – 5 min Not applicable  3 – 5 min 
Pralidoxime Initial Dose 1800 mg 1000 mg 1800 mg 1800 mg 1800 mg 
 Repeat Dose No 
instructions 
No 
instructions 
Not 
specified 
Not applicable, 
only 1800 mg 
carried in field  
1000 mg 
 Repeat Interval No 
instructions 
No 
instructions 
30 – 60 min, 
then hourly 
Not applicable  60 min 
(CDC, 2010; NYDH, 2005; USAMRICD, 2007) 
 
Human oxime studies 
Pralidoxime treatment for organophosphate poisoning has raised doubt as to how 
effective it may be, and studies have even concluded that it may be harmful (Eddleston 
and others, 2009).  Others have stated that the dosing used in these studies was too low 
and suggested a higher dose should be used, such as the dose recommended by the WHO 
(Eddleston and others, 2009).  A randomized controlled trial conducted by Eddleston and 
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others challenged the efficacy of pralidoxime in organophosphate insecticide poisoning 
(Eddleston and others, 2009).  They compared the results of a group receiving the WHO-
recommended dose of pralidoxime against a control group receiving a placebo (Eddleston 
and others, 2009).  Pralidoxime was successful at reactivating acetylcholinesterase in the 
blood compared to no reactivation occurring with the control group (Eddleston and 
others, 2009).   
Despite this reactivation of acetylcholinesterase, the researchers found that 
pralidoxime treatment resulted in a 69% increase in mortality (Eddleston and others, 
2009).  They concluded that the dose of pralidoxime recommended by the WHO “is most 
likely to be ineffective, and may be harmful” (Eddleston and others, 2009).  The 
researchers questioned that the dose may be too high, and may be more beneficial at 
lower doses (Eddleston and others, 2009).  The dose level recommended by the WHO is 
based on levels that are effective in in vitro studies and that the dose may not be the best 
in vivo dose for humans (Eddleston and others, 2009).  The researchers recommend that 
further study be conducted to find an effective oxime dose for use in human 
organophosphate poisoning (Eddleston and others, 2009). 
 
PBPK Modeling 
Physiologically-based pharmacokinetic (PBPK) modeling calculates the 
concentrations of chemicals over time in different tissues of the body.  The model 
contains physiological properties such as tissue volume, blood flow rate, and metabolic 
pathways.  PBPK models must also contain properties of the modeled chemical to include 
tissue solubility, metabolic rates, and routes of exposure (Andersen, 2003). 
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Mass balance equations are numerically integrated for each tissue to determine 
the concentration in the respective tissue over time.  Concentrations of particular 
chemicals in different tissues is dependent on pulmonary rate, tissue volume, tissue blood 
flow rate, tissue partition coefficients, and metabolic rates of the chemical in different 
tissues.  PBPK model parameters such as partition coefficients and metabolic rates are 
determined from extensive in vitro studies.  The use of PBPK modeling requires less 
funding, time, and animal subjects than traditional studies.  PBPK models can be 
validated by conducting similar in vivo experiments and comparing the data to the model 
output (Andersen, 2003). 
PBPK modeling uses data for absorption, distribution, metabolism, and excretion 
of a chemical within the body.  In vivo animal studies typically supply the required data 
for absorption, distribution, and excretion.  Metabolism data can often be estimated by 
fitting the model results to pharmacokinetic data.  Absorption into the body can occur 
through ingestion, inhalation, or dermal absorption.  Elimination of the chemical can 
occur through excretion in the urine or feces, exhalation, or metabolism (Hoang, 1995). 
The PBPK model used to conduct the research in this thesis assumes that 
chemical concentration within a tissue is homogenous and uses ordinary differential 
equations with respect to time to calculate the quantity of a chemical.  Partition 
coefficients are used within the mass balance when partitioning occurs within the tissue.  
(Hoang, 1995). 
Metabolism is a complex mechanism, but is implemented into PBPK models in 
the form of zero order, first order, or Michaelis-Menten kinetics.  The Vmax and Km 
required in the Michaelis-Menten equation are derived from in vitro and in vivo 
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measurements.  Most PBPK models make the assumptions that chemical transport is 
limited by flow,  assumes a homogenous chemical concentration within a tissue group, 
and that metabolism occurs in the liver and follows Michaelis-Menten kinetics (Hoang, 
1995). 
 
PBPK modeling of organophosphates 
The consideration of developing a PBPK model to estimate organophosphate 
behavior in the body can be traced to a study conducted by Maxwell and others in 1987 
(Maxwell and others, 1987).  That study looked at the inhibition of cholinesterase by 
soman in various organs and plasma of rats.  To determine important factors related to the 
in vivo and extent of cholinesterase inhibition, the researchers used a multiple regression 
model.  From the regression model, the researchers determined that blood flow, 
carboxylesterase, and cholinesterase, accounted for 94% of the variability (Maxwell and 
others, 1987).  Blood flow accounted for 79% of the variation, leading to the hypothesis 
that a PBPK model could be used to model the kinetics of soman influence on in vivo 
cholinesterase inhibition (Maxwell and others, 1987). 
In 1988, Maxwell and others furthered their research into the development of a 
pharmacodynamic model to determine the behavior of soman and acetylcholinesterase in 
rats.  Their model determined that the metabolism of soman in plasma contributed the 
most to changes in soman inhibition of acetylcholinesterase in the brain (Maxwell and 
others, 1988).  
Gearhart and others developed a PBPK model to describe how 
diisopropyfluorophosphate (DFP) affects acetylcholinesterase inhibition in mammals 
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(Gearhart and others, 1990).  The researchers used the model to look at the effects of 
repeated and prolonged exposures on acetylcholinesterase levels, a scenario that would be 
similar to an occupational setting.  The researchers concluded that this type of model may 
be useful for modeling organophosphate exposures in humans (Gearhart and others, 
1990). 
In 1994, Gearhart and others took the next step in PBPK modeling and developed 
a model for organophosphate exposure and acetylcholinesterase inhibition in humans 
(Gearhart and others, 1994).  The researchers developed the model to look at two 
different organophosphates, DFP and parathion.  DFP was chosen to act as a surrogate for 
other organophosphates such as nerve agents due to DFP having a similar behavior to 
these agents.  The model of parathion also had to include the metabolism of parathion to 
its more toxic metabolite, paraoxon.  The model parameters were determined from in 
vivo data from rats and then scaled for humans.  Both models were validated by 
comparing the model results to literature data from exposures to these chemicals.  The 
researchers concluded that this type of model could be used for other organophosphates 
as well (Gearhart and others, 1994). 
In 1997, Langenberg and others developed a physiologically-based model to 
investigate the behavior of two different types of stereoisomers of soman (Langenberg 
and others, 1997).  Different stereoisomers of soman exhibit different levels of toxicity 
and was the basis for the research conducted by Langenberg and others.   Their research 
led to the suggestion of expanding the model to four of the stereoisomers due to large 
variances in the biochemistry of the two groups that were initially investigated 
(Langenberg and others, 1997).  
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Timchalk and others developed a PBPK model in 2002 for chlorpyrifos, the active 
ingredient in some commercially available pesticides (Timchalk and others, 2002b).  The 
researchers used experimental data from rats and humans exposed to chlorpyrifos along 
with literature data to construct a model that exhibited the behavior seen in the 
experimental trials.  Their model was capable of describing human and rat response to 
chlorpyrifos exposure fairly well under acute and chronic exposures, as well as oral and 
dermal exposures.  The researchers concluded that the PBPK model used in the study 
would be a good starting point for other organophosphates models and could be used to 
perform risk assessments under multiple exposure scenarios.  In a later study, Timchalk 
and others used the PBPK model for chlorpyrifos to perform a Monte Carlo analysis of 
variability between individuals with regards to model inputs (Timchalk and others, 
2002a).  The researchers exhibited the ability of a PBPK model to determine the impact 
of variability amongst the model inputs when conducting a risk assessment (Timchalk 
and others, 2002a). 
In 2002, Gentry and others performed a similar analysis with the PBPK model for 
parathion developed by Gearhart and others (Gentry and others, 2002).  The researchers 
performed a Monte Carlo analysis to develop a method to evaluate how polymorphism in 
genes relates to dose variances in different tissues.  Like Timchalk and others, Gentry and 
others came to the conclusion that using a PBPK model with a Monte Carlo analysis is a 
useful method to characterize variances in tissue doses (Gentry and others, 2002). 
Poet and others developed and validated a PBPK model in 2004 to describe the 
behavior of another organophosphate pesticide, diazinon (Poet and others, 2004).  This 
model was based on the PBPK model built in 2002 by Timchalk and others for 
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chlorpyrifos.  The model developed by Gearhart and others in 1990 was also used during 
the development of their model.  The researchers were able to show that the PBPK model 
developed for diazinon was capable of estimating tissue concentrations and relating 
inhibition of cholinesterase to metabolism (Poet and others, 2004).  This model is yet 
another example of the usefulness of PBPK modeling of organophosphate poisoning. 
A model developed in 2004 by Ashani and Pistinner described the inhibition of 
acetylcholinesterase and butyrylcholinesterase by the nerve agents VX, soman, and sarin 
(Ashani and Pistinner, 2004).  The goal of the study was to determine the effectiveness of 
administering exogenous butyrylcholinesterase to bind with free nerve agent molecules in 
plasma.   The model developed was able to demonstrate that pretreatment with human 
butyrylcholinesterase should prevent symptoms of organophosphate poisoning (Ashani 
and Pistinner, 2004). 
Another PBPK model published in 2004 demonstrated the ability of PBPK 
modeling to handle interactions between multiple chemicals (El-Masri and others, 2004).  
The researchers developed the model to analyze the interaction between chlorpyrifos and 
parathion, as well as the metabolites of these two organophosphates, chlorpyrifos-oxon 
and paraxon respectively.  The model was composed of four PBPK models, one for each 
chemical of interest, with the models for the main chemicals and its metabolite linked at 
the liver (El-Masri and others, 2004).  The researchers were able to demonstrate that a 
PBPK model can successfully be applied to multiple chemicals (El-Masri and others, 
2004), an important consideration for modeling an organophosphate and its antidotes in a 
single model.   
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In 2005, Worek and others developed a model to demonstrate the effectiveness of 
different oximes in nerve agent poisoning (Worek and others, 2005).  The researchers 
built the model to look at the effectiveness of the oximes, obidoxime, pralidoxime, and 
HI 6, in response to poisoning by sarin, cyclosarin, and VX.  The model was validated by 
comparing the acetylcholinesterase levels predicted by the model to in vivo levels 
measured in a patient poisoned by parathion and treated with atropine and obodoxime.  
The researchers concluded that a dynamic model would be a capable tool for comparing 
various oximes, determining effective oxime concentrations, and for developing oxime 
treatment for organophosphate poisoning (Worek and others, 2005).  This emphasizes 
that accurate parameter values are needed for the oxime being used to ensure that the 
model output reflects what happens in a living environment. 
In 2006, the same group of researchers led by Aurbek, developed a model to look 
specifically at the effectiveness of the oxime HI 6 in VX poisoning (Aurbek and others, 
2006).  In 2007, the researchers led by Worek, expanded the model developed in 2005 to 
incorporate pretreatment by a carbamate such as pyridostigmine (Worek and others, 
2007).  Both sets of researchers show that the effectiveness of medical treatment for 
organophosphate poisoning can be analyzed with a PBPK model. 
Seaman developed a PBPK model in 2008 to describe the behavior of 
organophosphates and their antidotes, atropine and oxime, in humans (Seaman, 2008).  
His research aimed at determining the effectiveness of the antidotes that are widely used 
in practice.  He concluded that oximes were more effective when used against less toxic 
organophosphates such as commonly used insecticides, but less effective, or even 
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harmful, when the organophosphates had a higher toxicity, such as nerve agents (Seaman, 
2008). 
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III. Methodology 
Modeling Structure 
 The model simulations used during this research were performed with version 9.0 
of STELLA®, modeling software developed by isee Systems, Inc.  The model consisted 
of compartments for pulmonary, arterial, venous, brain, diaphragm, liver, fat, slowly 
perfused, richly perfused, thigh, and kidney tissues.  The model described the absorption, 
distribution, metabolism, and excretion of organophosphates, atropine, and oxime.  
Additionally, the model describes the behavior of acetylcholine, acetylcholinesterase, 
butyrylcholinesterase, and carboxylesterase.  The basic structure of the model is shown in 
Figure 1. 
 
Figure 1 - Simplified model structure 
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 Organophosphates were absorbed through inhalation into the pulmonary tissue 
and distributed through the arterial tissue to the rest of the system.  Atropine and oxime 
were absorbed by either intramuscular injection in thigh tissue or through intravenous 
injection in venous tissue.  Atropine and oximes were eliminated either through 
metabolism by enzymes in the liver or excretion in the urine from the kidneys.  
Acetylcholine and the esterases were naturally produced and degraded in each of the 
different tissue compartments. 
 Organophosphates, atropine, oxime, acetylcholine, and esterases interacted 
throughout the model through chemical reactions with one another.  Complexes involving 
organophoshates and the three esterases were also described by the model in each of the 
tissues.  Literature has indicated that following the reaction between the 
organophosphate-esterase complex with oxime, a complex of consisting of the 
organophosphate and oxime is formed.  This complex has been described to be an 
acetylcholinesterase inhibitor as well (Worek and others, 2004).  For model 
simplification, these complexes and pure organophosphate molecules were aggregated 
into solely organophosphate molecules.  
 
Equations 
 A full list of equations used with the model can be found in Appendix A.  A mass 
balance equation for each of the chemical components, organophosphates, atropine, 
oxime, acetycholine, and the three esterases, is calculated for each tissue compartment.  
The general form for each mass balance equation is shown in equation 1. 
          (1) 
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Inflows into the system can consist of inhalation in the lungs, intramuscular 
injection in the thigh tissue, or intravenous injection in the venous tissue.  The primary 
inflow into each tissue compartment is from the arterial blood compartment.  Outflows 
from the system are exhalation from the lungs, elimination in the urine, or metabolism.  
The primary outflow in each tissue compartment is blood flow out to the venous 
compartment. 
Generation and consumption occur in the tissue compartments through natural 
synthesis and degradation as well as through chemical reactions between the different 
chemical components.  The natural synthesis of esterases was zero-order and represented 
in each tissue by a synthesis constant.  Degradation of esterases was represented by a 
first-order process and was dependent on the esterase concentration within the tissue 
compartment.  The overall esterase concentration in each tissue was determined by 
equation 2. 
     (2) 
The interaction between the organophosphates and esterases are represented by the 
following chemical reaction. 
 
         (3) 
 
where 
ki = OP reaction rate coefficient with esterase (mol-1 time-1) 
ka = OP-esterase complex aging reaction rate coefficient (time-1) 
ks = OP-esterase complex natural separation reaction rate coefficient (time-1) 
ka 
ks 
ki 
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This chemical reaction is represented by the following differential equation. 
            (4) 
The interaction between the complex of OP and esterase with oxime is represented by the 
following chemical reaction. 
 
                       (5) 
where 
kr = OP-esterase complex reaction rate coefficient with oxime (mol-1 time-1) 
This chemical reaction is represented by the following differential equation. 
                   (6) 
The relationship between acetylcholine actively stimulating the nerve, 
acetylcholinesterase, and atropine is shown in equation (7).  The equation incorporates 
the effect atropine has on blocking the excess acetylcholine present in the synapse 
through the use of a ratio that decreases the rate of nerve stimulation by acetylcholine at 
the nerve receptors as the concentration of atropine increases.  The reaction between 
acetylcholine and acetylcholinesterase is represented by a second-order reaction (Seaman, 
2008). 
                   (7) 
where 
 p1 = acetylcholine binding rate (mass / time) 
 p2 = acetylcholine degradation constant (time-1) 
This equation simplifies to equation (8) when no atropine is present in the system. 
kr 
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                   (8) 
The model makes extensive use of a model output that is referred to as a symptom 
curve.  This output was developed to express the severity of symptoms that the patient is 
experiencing.  The value of the symptom curve is a ratio of the concentration of 
acetylcholine molecules that are actively stimulating the nerves over the concentration of 
active acetylcholine molecules at homeostasis.  When an organophosphate is introduced 
into the system, it binds with acetylcholinesterase molecules and prevents the breakdown 
of acetylcholine, causing the ratio and the symptom curve level to increase.  Introduction 
of atropine effectively blocks the nerve receptor cites, preventing acetylcholine from 
reaching these sites, effectively lowering this ratio and the symptom curve.  At 
homeostasis with no atropine or organophosphates present in the system, the symptom 
curve has a value of one.  The metric derived from the differential equation shown in 
equation (9) was one of the key metrics used to compare different treatment strategies.  
This metric evaluates symptoms at a particular point in time by comparing the 
concentration of acetylcholine at the nerve receptor sites to the basal concentration of 
acetylcholine at these sites.  While this metric provided an indication of the level of 
symptoms at any given time, in order to determine the overall effectiveness of a treatment 
over the course of the simulation, an additional metric was developed.   
           (9) 
As shown in equation (10), treatment effectiveness will be evaluated by 
calculating the time weighted average of the symptom curve with organophosphate 
exposure and antidote treatment and comparing it against the time weighted average of 
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the symptom curve with no exposure or treatment (Merrill and others, 2009).  It is simply 
a ratio of the area between the symptom curve and baseline of the simulation with an 
exposure and treatment over the area between the symptom curve and baseline of a 
patient without exposure or treatment.  Both the numerator and denominator of the ratio 
have units of hours, thus the normalized symptom curve area is a unitless number.  
       (10) 
 Using this method, a patient with no exposure or treatment has a normalized 
symptom curve area of 1.0.  The higher the value of the symptom curve area, the more 
harmful a particular scenario was to a patient. 
 
Assumptions 
There are several assumptions that are made with respect to the modeling of a 
living system.  As in most PBPK models, the model assumes instantaneous mixing and 
equilibrium of the different chemicals within a particular tissue.  Specifically to this 
model, metabolism of the chemicals by enzymes is assumed to be a saturable process 
using Michaelis-Menton kinetics that was determined through in vitro studies (Gearhart 
and other, 1994).  It is also assumed that the release of acetylcholine and diffusion across 
the synaptic cleft occurs instantaneously.  Additionally, it is assumed that 
organophosphate-oxime complexes behave the same as organophosphate molecules, thus 
can be lumped together as a single entity within the model.  
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Parameters and Coefficients 
 The parameters and coefficients used in the model were based on literature values 
or the model was used to fit the parameters to reproduce literature values.  Many of the 
values for the coefficients and parameters were retained from the values used in 
Seaman’s model.  A full list of the parameters and coefficients used within the model can 
be found in Appendix B. 
 The metabolic coefficients for atropine and oxime were determined from 
fitting the model to the half-life values and amount excreted in the urine that was cited in 
literature observations (Meridian Medical Technologies, 2007).  These values varied 
from the values used by Seaman as the values used in his research did not mimic the data 
found in literature.  Additionally, values for the kinetic rate constants of the 
organophosphate used were mainly based on the values by Seaman with a few 
exceptions.  The rate of inhibition was adjusted for BuChE to occur at a lower rate than 
AChE as literature values indicated that for very strong organophosphates such as VX, 
the inhibition of AChE can be up to two to three times as high as that for BuChE (Worek, 
2004).  To determine the symptom curve values in the model for when symptoms and 
death occurs, the value of the symptom curve was observed for the levels cited by Ashani 
and Pistinner.  Ashani and Pistinner suggest that symptoms occur when 
acetylcholinesterase levels in the tissues drop below 35% of basal levels and that a level 
of 10% of basal levels is required to sustain critical brain and diaphragm functions 
(Ashani and Pistinner, 2004).  At an inhibition of acetylcholinesterase levels to 35% of 
basal levels, a symptom level of 1.48 was observed.  At a level of 10% of basal levels, a 
symptom level of 1.90 was observed.  Based on these observations, it was assumed in all 
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simulations that symptoms began to occur with a symptom level of 1.48 and death occurs 
when the symptom level reaches 1.90.  The symptom curve has a value of 1.00 when no 
exposure to organophosphate or treatment with atropine has occurred.  When atropine is 
introduced into the system without an organophosphate exposure, the symptom curve 
levels drop below 1.00.  Literature suggests that atropine doses of 10 mg produce adverse 
effects in patients that have not been exposed to organophosphates (USARMICD 2007).  
To determine the symptom curve level associated with an adverse reaction from a dose of 
atropine, 10 mg of atropine was introduced to the model.  The symptom curve level 
dropped to a minimum value of 0.35.  For model simulations, a value of 0.35 was 
assumed to indicate adverse effects in the patient from overtreatment with atropine. 
The method used to determine the overall effectiveness of the treatment 
administered was the area under the symptom curve.  This method will account for 
duration and intensity of symptoms.  The area under the symptom curve was normalized 
by dividing the area under the symptom curve from a specific treatment by the area under 
the symptom curve without exposure or treatment.  Additionally, the minimum and 
maximum symptom curve levels were observed to determine the performance of a 
specific treatment. 
 
Simulation Protocol 
 The simulations were broken down into three sets, a set for intramuscular antidote 
administration, a set for intravenous antidote administration, and finally, a set for 
analyzing the current antidote treatment guidelines.  A full list of the simulation protocols 
can be found in Appendix C.  Each set was compared to a set of nine simulations with 
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varying organophosphate exposures, but without antidote treatment.  The nine 
simulations were composed of a combination of organophosphate exposures that lasted 5, 
15, and 30 minutes and caused mild, severe, or lethal symptoms.  For each simulation, the 
time that symptoms appeared, duration of symptoms, time of death, maximum symptom 
level, minimum symptom level, and total area under the symptom curve were recorded. 
 The first set of simulations consisted of administering atropine and pralidoxime 
intramuscularly.  For each dose of antidote, the same nine simulations of varying 
organophosphate exposure were used.  This set of intramuscular antidote administration 
was further broken down into 27 simulations of atropine treatment only, 27 simulations 
of pralidoxime only, and 81 simulations using both atropine and pralidoxime.  Atropine 
doses were 2 mg each and up to three doses were injected at times of 2, 17, and 32 
minutes after symptoms first appear. The strategy was similar for pralidoxime treatment 
with the exception of a 600 mg dose, rather than 2 mg.   
 The second set of simulations looked at administering atropine and pralidoxime 
intravenously.  The quantity for each dose was the same as the quantity used for 
administering intramuscularly, with the exception of the administering of the intravenous 
dose slowly over a period of time.  The timing varied with treatment being delayed to 
simulate the time required for the arrival of first responders or for the patient to arrive at 
the emergency room.  Atropine was administered up to three times at 15, 30, and 45 
minutes following the first appearance of symptoms, while pralidoxime was administered 
at 15, 45, and 75 minutes following the first appearance of symptoms.  Pralidoxime was 
administered slowly over a period of 20 minutes. 
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 Additionally, a set of simulations were run using the current recommendations 
established by the CDC, NYDH, and USAMRICD.  Each set of recommendations was 
run against each of the nine exposure scenarios.  These simulations helped determine the 
effectiveness or ineffectiveness of the current recommendations available to first 
responders and physicians.   
 The results of these simulations provided vital information that will indicate 
which therapeutic dosing strategies are the most effective at reducing symptoms, 
preventing death, as well as reducing the period of time that the patient experiences 
symptoms.  The treatment protocols were sorted and ranked based on their ability to 
reduce the severity of symptoms (intensity and duration), death, and their ability to move 
the patient towards recovery.  Based on the results of these preliminary simulations, 
additional simulations were performed to optimize the treatment guidelines. 
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IV. Results and Analysis 
Intramuscular treatment series 
 A detailed list of results for each exposure level and type of treatment along with 
the simulation protocols can be found in Appendix D.  The exposure concentrations for 
each of the three mild exposure durations varied in order to produce similar symptom 
levels across the set of mild exposures.  These different exposure durations were 
implemented to determine if exposure duration had an effect on treatment and treatment 
simulations were compared with a specific exposure only and not across all mild 
exposures.  This procedure was also used for the severe and lethal exposure sets.  The 
three different mild exposures all produced symptoms at approximately the same time in 
the model.  For the mild exposures, symptoms first appear from 81 to 85 minutes after 
exposure.  Additionally, the maximum symptom level ranged from1.66 to 1.73 and the 
normalized area under the symptom curve ranged from 1.42 to 1.43. 
All treatment scenarios involving atropine provided a benefit as compared to the 
organophosphate exposure alone to include all of the established treatment protocols.  
Conversely, oxime treatment alone without atropine treatment produced more harmful 
effects than the organophosphate exposure alone.  In all exposure scenarios and in each 
of the three oxime treatments without atropine, an increase in the maximum symptom 
level and area under the symptom curve occurred.  Additionally, a simulation involving 
the 30-minute mild exposure with a single oxime dose of 600 mg treatment produced a 
maximum symptom level of 1.86 as compared to 1.73 without treatment.  A symptom 
value of 1.86 also brought the patient close to the 1.90 symptom value for death. 
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The harmful effects of oxime treatment were also evident in treatments involving 
atropine.  While these treatments performed better than with no treatment administered, 
treatment with atropine alone performed better than a treatment with atropine and oxime.  
Simulations involving three different dosing strategies of atropine alone were compared 
with the same atropine dosing strategy with oxime treatment.  In each case, the atropine 
treatment alone resulted in a lower maximum symptom level and a smaller area under the 
symptom curve.  As shown in Figure 2, the symptom curve is elevated following the 
injection of the oxime dose as compared to treatment with atropine alone.  To further 
analyze this observation, the treatment scenario that performed the best with respect to 
area under the symptom curve was compared to an additional simulation performed with 
the same atropine dosing strategy, but without the oxime treatment.  As seen with the 
other simulations, the additional simulation without oxime treatment performed better 
than the same atropine treatment with oxime administered.  In fact, this additional 
simulation with atropine alone was the best performer of all the treatment scenarios for 
this particular exposure.  The model confirms that oxime treatment administered at the 
same time as atropine provides no benefit for mild exposures. 
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Figure 2 - Effect of oxime use on symptom level 
To determine if an alternate treatment method would enable the use of oxime 
treatment without having an increase in severity of symptoms at the point of injection, a 
simulation with an oxime injection delayed 10 minutes following the first atropine 
treatment was performed.  Small doses of oxime, such as 600 mg, caused the overall area 
under the symptom curve to increase and also caused symptoms to be prolonged.  A 
second simulation using 2000 mg produced a lower area under the symptom curve, but as 
with the first simulation, symptoms occurred for a longer period of time.  Additionally, 
shortly following the injection of oxime, the symptom level had a second peak that was 
higher than the first peak before atropine began to reduce symptoms.  A 10-minute delay 
in administering oxime did not prevent the symptom level from peaking higher than 
treatment without oxime.  An additional simulation delaying the 2000 mg injection of 
oxime until 20 minutes had passed from the start of atropine treatment proved to provide 
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a reduction in area under the symptom curve without having a symptom level increase 
above atropine treatment alone.  Symptoms occurred with this treatment for 10 minutes 
longer than with atropine treatment alone.  The benefits of the delayed oxime treatment 
can be seen with the levels of acetylcholinesterase at the end of simulation.  With 
atropine treatment alone, acetylcholinesterase levels were 43.5% of basal levels, while 
levels were at 62.5% of basal levels with the oxime treatment.   
Optimization of atropine treatment was required as increasing doses of atropine 
produced better results with respect to the area under the symptom curve.  As a safeguard 
against an atropine treatment being administered to a patient that had not been exposed to 
an organophosphate, only individual doses of atropine smaller than 10 mg were 
investigated.  Evaluation of increasing atropine dosing of 1 mg between simulations 
revealed that increasing dosage provided an added benefit.  Each additional milligram of 
atropine provided a diminishing benefit.  To determine the optimal dosage, the additional 
dosage of atropine as a percentage of the previous simulation was compared to the 
additional benefit provided to the area under the symptom curve.  As an example, 
increasing the dosage from 1 to 2 mg, a 100% increase in dose, reduced the area under 
the curve from 1.3552 to 1.3195, a 2.64% decrease.  This produced a ratio between the 
two percentages of 0.0264.  A lower value reflects less additional benefit for a particular 
dose increase than a higher value would have.  This value continues to increase for each 
subsequent increase of atropine up to 5 mg, after which, this ratio begins to decrease, 
indicating that approximately 5 mg of atropine is an optimal dose for this particular 
exposure.  This ratio with respect to atropine dose is shown in Figure 3.  This method 
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produced similar results for each of the three mild exposures, with 5 mg of atropine 
proving to be the optimal initial dose of atropine for mild exposures. 
 
Figure 3 - Benefit of initial dose quantity of atropine 
The next step in the optimization process involved the repeated doses of atropine 
and the subsequent timing.  As may be expected, as time between the initial dose and the 
second dose increased, the overall effectiveness of the treatment decreased.  The optimal 
timing of a repeat dose would be as soon as possible following the previous dose.  
Ideally, this time between doses should be long enough to determine if the previous dose 
was sufficient to treat the patient.  For all mild exposures, the initial dose of 5 mg reduced 
patients below a symptomatic level fairly rapidly.  Based on these findings, a repeat dose 
10 minutes following the preceding dose would likely provide optimal benefits as well as 
provide enough time between doses to evaluate the patient’s condition. 
The final step in determining the optimal treatment was to determine the optimal 
dose of the repeat doses.  As with the initial dose, increasing the dosage of the second 
dose increased the benefit to the patient with respect to the area under the symptom 
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curve.  Additionally, there was no change observed in the maximum symptom level.  The 
initial atropine treatment caused the symptom curve to decline from the point of injection 
and all subsequent doses were injected at a lower symptom level than that at the time of 
the first injection.  For the quantity of the repeat doses, the additional benefit of the 
atropine decreased with an increasing quantity of atropine per dose. Therefore, a 1 mg 
dose was selected for repeat doses.  The performance of this guideline to treat an 
exposure that produces mild symptoms is shown in Figure 4. 
 
Figure 4 - Exposure causing mild symptoms with one atropine dose (5 mg) and a delayed 
dose of oxime (1000 mg) 
 
The three different severe exposures all produced symptoms and death at 
approximately the same time in the model.  The time when symptoms first appear ranged 
from 53 to 66 minutes following exposure and the occurrence of the death ranged from 
166 to 174 minutes following exposure.  Additionally, the maximum symptom level 
ranged from 1.90 to 1.91 and the normalized area under the symptom curve ranged from 
1.53 to 1.58. 
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As was seen with the simulations performed with a mild exposure, oxime 
treatment appeared to cause more harm than treatment with atropine alone.  To further 
illustrate this, the top ranked simulation based on area under the symptom curve was 
performed under the same conditions, but without oxime treatment.  The simulation with 
only atropine treatment proved to produce a lower maximum symptom level as well as a 
lower area under the symptom curve.  Although, delaying the oxime treatment for 20 
minutes after the initial atropine injected increased acetylcholinesterase activity and did 
not increase the maximum symptom level. 
 
Figure 5 - Exposure causing severe symptoms with three atropine doses (one 6 mg dose 
and two 1 mg doses) and a delayed dose of oxime (2000 mg) 
 
Optimization of the atropine treatment was performed for this set of exposures as 
had been performed on the mild symptom group.  As the dose of atropine increased, the 
level of symptoms continued to decrease.  Determining the optimal dose was required 
and the method used for mild symptoms was employed.  It was determined that 6 mg of 
atropine was the optimal dose for the initial dose of atropine.  Additionally, a repeat dose 
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of 1 mg was determined to be optimal at decreasing symptoms.  The sooner the repeated 
dose was administered, the quicker that the patient stopped experiencing symptoms.  A 
time period of 10 minutes was assumed to be an adequate time between injections to 
reassess the patient to determine if atropine treatment should continue.  This treatment 
recommendation was simulated with an exposure that produces severe symptoms and is 
shown in Figure 5. 
The three different lethal exposures all produced symptoms and death at 
approximately the same time in the model.  The time that symptoms first appeared ranged 
from 36 to 44 minutes and the time that death occurred ranged from 82 to 85 minutes 
after exposure.  Additionally, the maximum symptom level ranged from 2.20 to 2.27 and 
the normalized area under the symptom curve ranged from 1.78 to 1.79. 
When comparing the treatment scenarios involving atropine alone against 
atropine with oxime, a noticeable difference occurred that had not been noted in the mild 
and severe scenarios.  While the simulations involving just atropine proved to cause a 
lower maximum symptom level as compared to the same atropine treatment along with 
oxime, the area under the symptom curve was lower with the oxime treatment.  This 
difference appears to occur due to how the simulations were performed.  Since treatment 
begins after the first sign of symptoms (1.48 on the symptom curve), treatment occurs 
sooner with the higher exposures in the lethal exposure group.  Additionally, oxime 
treatment does provide a benefit of reducing the severity of symptoms more rapidly over 
atropine treatment alone.  Despite this benefit, in every simulation performed to compare 
the benefits of oxime treatment to no oxime treatment, the simulations with oxime 
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treatment always had a higher maximum symptom level than the simulation without 
oxime treatment. 
As with other levels of organophosphate exposure, increasing quantities of 
atropine treatment produced better results in a patient.  Therefore, optimization of 
atropine treatment was required.  As was seen in previous simulations, each additional of 
1 mg of atropine in an initial dose provided additional protection against 
organophosphate poisoning, but with each additional milligram of atropine provided a 
diminishing benefit.  To determine the optimal dosage, the additional dosage of atropine 
as a percentage of the previous simulation was compared to the additional benefit 
provided to the area under the symptom curve.  Using the same method of optimizing the 
atropine dose revealed an optimal dose of 6 mg.  This method produced similar results for 
each of the three lethal exposures, and 6 mg of atropine was determined to be the optimal 
initial dose for lethal exposures. 
With the optimal initial dose determined, the optimization of repeat doses was 
performed.  As seen in other simulated exposure scenarios, a patient’s symptoms improve 
sooner when a repeated dose is administered soon after the previous dose.  With the same 
reasoning as before and for a simpler set of recommendations, a 10-minute time interval 
between doses was chosen for severe symptoms. 
The final step in determining the optimal treatment was to determine the optimal 
dose of the repeat doses.  As with the initial dose, increasing the second dose increased 
the benefit to the patient with respect to the area under the symptom curve.  Additionally, 
there was no change observed in the maximum symptom level.  The optimal dose 
determined for the repeat dose of atropine was 1 mg.  To evaluate this treatment method 
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to determine if a 1 mg dose is an optimal dose, additional simulations were performed.  A 
simulation was performed to determine the number of 1 mg doses that would be required 
to reduce the symptoms below 1.48 on the symptom curve. The simulation determined 
that eight doses (8 mg) were required.  Repeating this method using 2 mg doses resulted 
in seven doses (14 mg) of atropine being required to reduce the symptom level below 
1.48.  This verified that the 1 mg dose for a repeat dose was more optimal than a 2 mg 
dose due to requiring a smaller quantity of atropine to alleviate symptoms in the patient.  
To verify this treatment guideline, a simulation was performed with a lethal dose of 
organophosphate and the results of the treatment are shown in Figure 6.  In this scenario, 
atropine treatment began with a 7 mg dose 2 minutes after the symptom curve reached 
1.48 and continued with 1 mg repeat doses at 10 minute intervals until symptoms 
dropped below 1.48.  Oxime treatment began with a 2000 mg dose 20 minutes after the 
first atropine dose.  The symptom level continued to drop following the cessation of 
treatment and stabilized at a level well below symptom levels, but above levels that 
would cause adverse effects due to atropine toxicity. 
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Figure 6 - Exposure causing severe symptoms with three atropine doses (one 6 mg dose 
and eight 1 mg doses) and a delayed dose of oxime (2000 mg) 
 
A potential issue involved with a delayed oxime treatment is significant aging will 
occur with organophosphates that age more quickly, such as soman.  To illustrate this in 
the model, the organophosphate in the model was adjusted to age more quickly with 
acetylcholinesterase and butyrylcholinesterase; carboxylesterase does not age with the 
organophosphate in the model.  The oxime treatment with this organophosphate made the 
acetylcholinesterase levels lower at the end of the simulation as compared to levels with 
atropine treatment alone.  This can be partly explained by the oxime freeing the 
organophosphate molecules that were bound to the carboxylesterase and were then 
available to bind with acetylcholinesterase.  Therefore, the use of oxime treatment proves 
to be beneficial with organophosphates that do not age quickly, such as pesticides.   
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Intravenous treatment series 
 The organophosphate exposures for the intravenous treatment series are the same 
as the exposures used for the intramuscular treatment series.  The treatment for this series 
is introduced intravenously and is represented in the model with an input directly into the 
venous tissue compartment.  In theory, this should distribute the antidotes more quickly 
and efficiently than an intramuscular injection.  The same method to determine the 
optimal dose of atropine was used for intravenous treatment as was used for 
intramuscular treatment.  The difference between the two treatment methods is that the 
intravenous method was administered slowly over a 10-minute period beginning 15 
minutes after symptoms present compared to a single injection 2 minutes after symptoms 
present.  The optimal dose of atropine for a mild exposure proved to be 4 mg over the 10-
minute period.  This amount can also be expressed as 0.4 mg/min or 24 mg/hr.  At the 
end of the 10-minute interval, a 5-minute period with the IV line turned off was assumed 
to be an adequate time period to reassess the patient’s symptoms.  If symptoms persist, 
additional doses should be administered.  The same rate of administering atropine should 
be repeated over additional 10-minute intervals until symptoms of organophosphate 
poisoning disappear. 
 The procedure was repeated for the severe exposure scenarios and a dose of 6 mg 
of atropine slowly over 10 minutes was determined to be the optimal dose for this 
exposure.  This corresponds to a rate of administration of 0.6 mg/min or 36 mg/hr.  As 
with treatment for mild exposures, this rate should be repeated over 10-minute intervals 
with a 5-minute period between doses to assess the patient’s symptoms.  Treatment 
should continue until the symptoms of organophosphate poisoning cease. 
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Finally, evaluation of the optimal IV dose of atropine for the lethal exposure set 
was performed.  A dose slightly higher than for the severe exposures, 7 mg over 10 
minutes, was deemed to be the optimal dose.  This corresponds to a rate of 0.7 mg/min or 
42 mg/hr. The procedure for repeated doses is the same as was described for mild 
symptoms with 10 minutes of treatment followed by a 5-minute assessment period.  
Treatment should continue until symptoms are no longer present.  The performance of 
this treatment protocol for intravenous introduction of antidotes was evaluated in the 
model and the results are shown in Figure 7.  In this scenario, atropine treatment began 
15 minutes following the presentation of symptoms with oxime treatment following 20 
minutes after the start of atropine treatment.  The exposure required two full 10-minute 
treatments minutes and the third interval being turned off once symptom levels dropped 
below 1.48.  Symptom levels stabilized below the level required for symptoms to appear 
in the patient at a time period 6 hours following exposure. 
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Figure 7 - Exposure causing severe symptoms with IV treatment of atropine and a 
delayed dose of oxime (2000 mg) 
 
With the atropine treatment optimization complete, an evaluation of another 
potential treatment scenario that could take advantage of the beneficial properties of 
oxime was performed by delaying the oxime treatment by 15 minutes following the 
treatment with atropine.  This method showed promise as it would allow atropine to fully 
circulate the system and begin lowering the symptom level prior to the spike seen with 
oxime treatment in other scenarios.  A 5-minute lethal exposure was treated with the 
optimal dosing strategy developed earlier and the time symptoms ended, 1.387 hours 
from the beginning of the simulation, and the normalized area under the symptom curve, 
1.31, were noted.  The second simulation treated the patient with 600 mg of oxime slowly 
over a 20-minute period.  The oxime treatment was not introduced until 15 minutes 
following the beginning of atropine treatment.  With this treatment, symptoms occurred 
until 1.481 hours following the start of the simulation and a normalized area under the 
symptom curve of 1.33; thus, both metrics proved to be worse than with the atropine 
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treatment alone.  A higher dose of oxime administered over a shorter time period proved 
to be more effective.  A 2000 mg oxime dose over 10 minutes reduced the normalized 
area under the symptom curve to 3.77 while not increasing the maximum symptom level 
seen with atropine treatment alone.  Symptoms do occur for a longer period of time under 
this treatment scenario, lasting until 1.437 hours after the beginning of the simulation. 
 Although it appears that this treatment protocol with oxime would be a successful 
method of taking advantage of the beneficial properties of oximes, a closer look at 
whether this trend would continue with an organophosphate that ages more quickly is 
warranted.  As was done with the intramuscular series, an organophosphate that ages 
more quickly was introduced into the model and the same treatment guidelines were 
administered.  Results similar to those found during the intramuscular series occurred 
with the intravenous treatment.  Acetylcholinesterase levels, total area under the 
symptom curve, and the symptom level at the end of the simulation were all worse than 
with atropine treatment alone.  Delaying oxime treatment has several risks involved.  
First, the longer duration between exposure to the organophosphate and the first 
treatment of oxime is long enough to allow significant aging to occur with strong 
organophosphates such as nerve agents.  Second, organophosphates that have not aged 
are released to bind with all available esterase. 
  
53 
 
V. Discussion 
Research Objectives 
1. Validate the physiologically-based pharmacokinetic (PBPK) model produced by 
Seaman and modify it as necessary to perform the simulations required to complete 
this research 
The model developed by Seaman was thoroughly analyzed and modified as needed 
prior to any simulations performed for this research.  The modifications performed on the 
model included both functional and aesthetic changes.  In order to evaluate intravenous 
treatment methods during this research, inputs were added for atropine and oxime that 
introduced a quantity of these antidotes directly to the venous compartment.  The model 
developed by Seaman used unconventional parameters that are not typically seen in 
PBPK modeling.  Specifically, the model included “normalization factors” for each tissue 
type that described the volume of a specific tissue with respect to total body weight.  The 
normalization factors were replaced in favor of tissue volume parameters to conform to a 
traditional PBPK model format.  A tissue concentration for each component was added 
using the mass of the particular component in that tissue and the tissue volume.  
Additionally, in kinetic equations, the use of mass in the equations was eliminated in 
favor of tissue volume and concentration.  This format is more consistent with traditional 
PBPK models and mass balance equations involving kinetics.  The final functional 
modification to the model was the adjustment of the metabolic rates of degradation of 
atropine and oxime.  The metabolic parameters were adjusted to fit to the data for a 
DuoDote autoinjector that contains both atropine and pralidoxime (Meridian Medical 
Technologies, 2007). 
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2. Analyze the current therapeutic strategies using the validated PBPK model in various 
exposure situations to determine if they are effective or cause harm 
 
The treatment guidance developed by the CDC, NYDH, USAMRICD, and WHO was 
analyzed with the model for a variety of scenarios.   Based on the simulation results, all 
of the treatment scenarios improved the patient’s health as opposed to not receiving any 
treatment at all.  Despite this fact, none of the guidance that was examined during this 
research was the optimal use of the antidotes available.  The use of oximes in any 
particular treatment scenario caused a momentary spike in maximum symptoms as 
compared to treating with atropine alone.  This is important to note as that spike in 
symptoms may be the difference in the patient dying or surviving.  The benefits of oxime 
use are clearly seen in the simulation results as well.  Oxime treatment increases the 
concentration of available acetylcholinesterase in the body to break down acetylcholine 
and causes the symptom curve to decline at a faster rate than with atropine treatment 
alone. 
The use of oxime to treat organophosphate poisoning has significant risks and 
benefits that need to be carefully examined before treatment with oxime is advised.  The 
risk of the patient dying as a result of receiving a treatment including oxime clearly 
increases as the symptoms of the patient are more severe.  Therefore, medical personnel 
should reconsider treating patients with oximes for severe organophosphate poisoning.  
Unfortunately, patients with severe exposures are in the most need of the beneficial 
properties of oxime treatment. 
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Conversely, the use of oximes while treating a patient with mild symptoms is not 
likely to cause a large enough increase in severity of symptoms to cause death.  Even 
without oxime treatment, a patient with a mild exposure will have a sufficient quantity of 
unbound acetylcholinesterase available to sustain primary life functions, and the model 
suggests that atropine treatment alone is effective in alleviating the symptoms a patient 
may be experiencing.  Based on the data from the simulations performed with 
simultaneous introduction of atropine and oxime, oxime treatment either posed a 
significant risk of causing harm (severe exposures) or had limited effectiveness over 
atropine treatment alone (mild exposures).  Delaying the oxime treatment until after 
atropine treatment has begun appears to provide beneficial results for relatively weak 
organophosphates.  Neither initial dosing with atropine and oxime, nor delaying oxime 
treatment for strong organophosphates was beneficial for the patient   Consequently, an 
optimized treatment strategy of initially treating with atropine alone followed by a 
delayed treatment with oxime was developed only for weak organophosphates such as 
pesticides while another strategy was developed for strong organophosphates such as 
nerve agents, involving only atropine. 
 
3. Develop a set of guidelines that provides an optimal dosing and timing strategy for 
various exposure situations to include military, terrorist, or occupational exposures to 
reduce death among initial survivors and hasten full recovery. 
 
The potential of oximes to cause harm was clearly evident in the results of this 
research. Due to their potential to cause the symptoms of a patient to worsen or even 
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cause death, the guidelines developed here do not recommend their use as recommended 
by current guidelines.  In order to receive the beneficial effects of oxime treatment 
without the spike in symptoms that occurs upon injection, oxime treatment must be 
delayed to a point after atropine treatment has begun.  Consequently, atropine treatment 
is advised immediately followed by a delayed treatment with oximes.  With the use of the 
model, an optimal dose of atropine was examined for an initial dose, repeat doses, and the 
subsequent timing between these doses.  This optimization was performed for varying 
levels of organophosphate exposure to determine if the quantity of organophosphate 
present affects the optimal atropine dosing required.  
 
Recommendations 
 The primary goal of this research was to develop a set of treatment guidelines for 
organophosphate poisoning based on simulations performed with a PBPK model.  The 
guidelines are presented in the following four tables, two for exposure to weak 
organophosphates and two for exposure to strong organophosphates or if the type of 
organophosphate is unknown.  Tables 3 and 4 are designed to treat exposures to weak 
organophosphates and have separate guidelines based on the severity of the symptoms.  If 
any severe symptoms are present, the medical provider should use the set of guidelines 
for severe symptoms.  The symptoms are based on the CDC definition of mild to 
moderate symptoms that include localized sweating, muscle twitching, nausea, vomiting, 
muscle weakness, and dyspnea and severe symptoms that include unconsciousness, 
convulsions, apnea, and paralysis (CDC, 2010).  If intravenous treatment is available, this 
method should be used to begin treating the patient.  Intramuscular treatment would 
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ideally be used in the field outside of a medical treatment facility when the only method 
of treatment available is autoinjectors. 
 
Table 3.  Intramuscular treatment for weak organophosphates (pesticides) 
  Mild/Moderate 
Symptoms 
Severe Symptoms 
Atropine Initial Dose 5 mg 6 mg 
 Repeat Dose 1 mg 1 mg 
 Repeat Interval 
until symptoms are 
no longer present 
10 min 10 min 
Pralidoxime Initial Dose 1000 mg 2000 mg 
 Timing 20 min after first 
atropine treatment 
20 min after first 
atropine treatment 
 Repeat dose None None 
 
 
Table 4.  Intravenous treatment for weak organophosphates (pesticides) 
  Mild/Moderate 
Symptoms 
Severe Symptoms 
Atropine Initial dose 0.4 mg/min  
for 10 min 
0.7 mg/min  
for 10 min 
 Repeat dose 0.4 mg/min  
for 10 min 
0.7 mg/min  
for 10 min  
 Repeat interval 
until symptoms are 
no longer present 
5 min 5 min 
Pralidoxime Initial dose 100 mg/min 
 for 10 min 
200 mg/min 
 for 10 min 
 Timing 20 min after first 
atropine treatment 
20 min after first 
atropine treatment 
 Repeat dose None None 
 
 Tables 5 and 6 are designed to treat exposures to strong organophosphate or if the 
type of organophosphate exposed to is unknown.  These two tables also include separate 
guidance for the degree of symptoms that the patient is experiencing.  The notable 
difference between the two treatment guidelines is that oximes are not recommended 
treatment for exposure to strong organophosphates.  If the type of organophosphate is 
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unknown, medical treatment should defer to the set of guidelines for treating nerve 
agents.  It should be noted that the same atropine treatment is used regardless of the type 
of organophosphate exposed to.  If symptoms reappear after treatment has ceased, 
treatment should continue where left off with continuing treatment with the repeat dosing 
presented in the tables.  Additionally, if the intravenous treatment becomes available 
subsequent to intramuscular treatment, treatment should transition to intravenous 
treatment. 
Table 5.  Intramuscular treatment for strong organophosphates (nerve agents) 
  Mild/Moderate 
Symptoms 
Severe Symptoms 
Atropine Initial Dose 5 mg 6 mg 
 Repeat Dose 1 mg 1 mg 
 Repeat Interval 
until symptoms are 
no longer present 
10 min 10 min 
Pralidoxime Initial Dose None None 
 
 
Table 6.  Intravenous treatment for strong organophosphates (nerve agents) 
  Mild/Moderate 
Symptoms 
Severe Symptoms 
Atropine Initial dose 0.4 mg/min  
for 10 min 
0.7 mg/min  
for 10 min 
 Repeat dose 0.4 mg/min  
for 10 min 
0.7 mg/min  
for 10 min 
 Repeat interval 
until symptoms are 
no longer present 
5 min 5 min 
Pralidoxime Initial dose None None 
 
For deployed military members in the field, Table 5 would be the only table used.  
This is significant since military members are currently issued auto-injectors with both 
antidotes and Table 5 does not recommend oxime use.  The guidelines for military 
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members in the field pose a significant risk and may cause symptoms of exposed 
personnel to worsen following treatment. 
These guidelines are based on the patient being an adult male of average size.  
Additional research and simulations would be required to develop a set of guidelines for 
children, the elderly, and females due to physiological differences such as body 
composition and weight.  Other potential antidotes such as butyrylcholinesterase would 
require minor model modifications to determine if they would improve the survival and 
aid in reducing symptoms.   
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Appendix A – Equations 
 
Organophosphates 
 Slowly Perfused, Thigh, Diaphragm, and Fat Tissues 
   
 Brain, Liver, Kidney, and Richly Perfused Tissues 
 
 Venous Tissue 
 
 Lung Tissue 
 
 Arterial Tissue 
 
 
Oxime 
 Brain, Diaphragm, Fat, Richly Perfused, Slowly Perfused Tissues 
 
 Kidney Tissue 
 
 Liver Tissue 
 
Thigh Tissue 
 
 Venous Tissue 
 
 Arterial Tissue 
 
 
Atropine 
 Brain, Diaphragm, Fat, Richly Perfused, Slowly Perfused Tissues 
 
 Kidney Tissue 
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 Liver Tissue 
 
Thigh Tissue 
 
 Venous Tissue 
 
 Arterial Tissue 
 
 
Acetylcholinesterase 
 Brain, Kidney, Diaphragm, Liver, Slowly Perfused, Richly Perfused, and Thigh 
Tissues 
 
 
Butyrylcholinesterase 
Brain, Kidney, Diaphragm, Liver, Slowly Perfused, Richly Perfused, and Thigh 
Tissues 
 
Carboxylesterase 
 Brain, Kidney, Diaphragm, Liver, Slowly Perfused, Richly Perfused, and Thigh 
Tissues 
 
 
Acetylcholinesterase and Organophosphate Chemical Reaction 
 
 
Butyrylcholinesterase and Organophosphate Chemical Reaction 
 
 
Carboxylesterase and Organophosphate Chemical Reaction 
 
 
Oxime and Acetylcholinesterase-organophosphate complex chemical reaction 
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Oxime and Butyrylcholinesterase-organophosphate complex chemical reaction 
 
 
Oxime and Carboxylesterase-organophosphate complex chemical reaction 
 
 
Atropine, Acetylcholine, and Acetylcholinesterase reaction 
 
 
Symptoms 
 
 
List of Symbols 
VT = Volume of tissue (volume) 
 = change in chemical concentration with respect to time (mass volume-1 time-1) 
FT = Fraction of blood flow that enters the tissue (unitless) 
QC = Cardiac Output (volume / time) 
CA = Chemical concentration in arterial tissue (mass / volume) 
CT = Chemical concentration in tissue (mass / volume) 
P = Tissue to blood partition coefficient (unitless) 
Vmax = Maximum metabolism rate (mass / time) 
Km = Michaelis-Menten Constant (mass / volume) 
VV = Volume of venous tissue (volume) 
CV = Chemical concentration in venous tissue (mass / volume) 
QP = Pulmonary ventilation rate (volume / time) 
Cair = Chemical concentration in air (mass / volume) 
VA = Volume of arterial tissue (volume) 
CL = Chemical concentration of blood from lungs (mass / volume) 
E = Elimination fraction of chemical in urine (unitless) 
IM = Intramuscular (IM) injection rate (mass / time) 
IV = Intravenous (IV) injection rate (mass / time) 
X1 = Acetylcholinesterase synthesis rate (mass / time) 
X2 = Acetylcholinesterase degradation rate (time-1) 
Y1 = Butyrylcholinesterase synthesis rate (mass / time) 
Y2 = Butyrylcholinesterase degradation rate (time-1) 
Z1 = Carboxylesterase synthesis rate (mass / time) 
Z2 = Carboxylesterase degradation rate (time-1) 
  
63 
 
ki = Organophosphate reaction rate coefficient with esterase (mol-1 time-1) 
ks = Organophosphate-esterase complex natural separation reaction rate coefficient (time-
1) 
ka = Organophosphate-esterase complex aging reaction rate coefficient (time-1) 
kr = Organophosphate-esterase complex reaction rate coefficient with oxime(mol-1 time-1) 
p1 = Acetylcholine binding rate (mass / time) 
p2 = Acetylcholine degradation constant (time-1) 
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Appendix B – Parameters 
 
Physiological Parameters 
   Body Weight 60.9 kg Gearhart et. al. 
Cardiac Output 302 L/hr Gearhart et. al. 
Pulmonary Rate 354 L/hr Gearhart et. al. 
Blood Flow to Tissue Fractions 
   
 
Brain 0.134 
 
Gearhart et. al. 
 
Diaphragm 0.006 
 
Gearhart et. al. 
 
Fat 0.036 
 
Gearhart et. al. 
 
Kidney 0.223 
 
Gearhart et. al. 
 
Liver 0.27 
 
Gearhart et. al. 
 
Richly Perfused 0.2 
 
Gearhart et. al. 
 
Slowly Perfused 0.1244 
 
Gearhart et. al. 
 
Thigh 0.0066 
 
Gearhart et. al. 
Tissue Volumes 
   
 
Arterial 1.218 L Gearhart et. al. 
 
Brain 1.30326 L Gearhart et. al. 
 
Diaphragm 0.1827 L Gearhart et. al. 
 
Fat 10.353 L Gearhart et. al. 
 
Kidney 0.26187 L Gearhart et. al. 
 
Liver 2.436 L Gearhart et. al. 
 
RPT 2.08887 L Gearhart et. al. 
 
SPT 31.89942 L Gearhart et. al. 
 
SPT Thigh 1.68084 L Gearhart et. al. 
 
Venous 3.4713 L Gearhart et. al. 
     Organophosphate 
   Molecular Weight 184 mg/mmol Seaman 
Partition Coefficents 
   Tissue -Blood Partition Coefficients 
   
 
Air-Blood 12.57 
 
Gearhart et. al. 
 
Arterial 1 
 
Assumed 
 
Brain 0.67 
 
Gearhart et. al. 
 
Diaphragm 0.77 
 
Gearhart et. al. 
 
Fat 17.6 
 
Gearhart et. al. 
 
Kidney 1.63 
 
Gearhart et. al. 
 
Liver 1.53 
 
Gearhart et. al. 
 
RPT 0.67 
 
Gearhart et. al. 
 
SPT 0.77 
 
Gearhart et. al. 
 
SPT Thigh 0.77 
 
Gearhart et. al. 
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Venous 1 
 
Assumed 
Metabolic Parameters 
   Km 
   
 
Arterial 199 mg/L Gearhart et. al. 
 
Brain 440 mg/L Gearhart et. al. 
 
Kidney 134 mg/L Gearhart et. al. 
 
Liver 237 mg/L Gearhart et. al. 
 
RPT 51 mg/L Gearhart et. al. 
 
Venous 199 mg/L Gearhart et. al. 
Vmax 
   
 
Arterial 216 mg/hr Gearhart et. al. 
 
Brain 688 mg/hr Gearhart et. al. 
 
Kidney 5042 mg/hr Gearhart et. al. 
 
Liver 52474 mg/hr Gearhart et. al. 
 
RPT 560 mg/hr Gearhart et. al. 
 
Venous 616 mg/hr Gearhart et. al. 
     Oxime (Pralidoxime) 
   Molecular Weight 137 mg/mmol Calculated 
Partition Coefficients 
   
 
Arterial 1 
 
Seaman 
 
Brain 0.67 
 
Seaman 
 
Diaphragm 0.77 
 
Seaman 
 
Fat 17.6 
 
Seaman 
 
Kidney 1.63 
 
Seaman 
 
Liver 1.53 
 
Seaman 
 
RPT 0.67 
 
Seaman 
 
SPT 0.77 
 
Seaman 
 
SPT Thigh 0.77 
 
Seaman 
 
Venous 1 
 
Seaman 
Metabolic Parameters 
   
 
KM Liver 700 mg/L Scaled from Meridian 
 
Vmax Liver 6500 mg/hr Scaled from Meridian 
Kidney Partition Parameter 
   
 
Elimination Partition 0.35 
 
Scaled from Meridian 
     Atropine 
   Molecular Weight 289 mg/mmol Calculated 
Partition Coefficients 
   
 
Arterial 1 
 
Seaman 
 
Brain 0.67 
 
Seaman 
 
Diaphragm 0.77 
 
Seaman 
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Fat 17.6 
 
Seaman 
 
Kidney 1.63 
 
Seaman 
 
Liver 1.53 
 
Seaman 
 
RPT 0.67 
 
Seaman 
 
SPT 2.1 
 
Seaman 
 
SPT Thigh 2.1 
 
Seaman 
 
Venous 1 
 
Seaman 
Metabolic Parameters 
   
 
KM Liver 700 mg/L Scaled from Meridian 
 
Vmax Liver 6500 mg/hr Scaled from Meridian 
Kidney Partition Parameter 
   
 
Elimination Partition 0.35 
 
Scaled from Meridian 
     Acetylcholinesterase 
   Molecular Weight 75,000 mg/mmol Assumed 
Synthesis Rate 
   
 
Arterial 0.0001 µmol/hr Gentry et. al. 
 
Brain 0.00002 µmol/hr Scaled from Gentry et. al. 
 
Diaphragm 0.000003 µmol/hr Scaled from Gentry et. al. 
 
Kidney 0.000004 µmol/hr Scaled from Gentry et. al. 
 
Liver 0.00004 µmol/hr Scaled from Gentry et. al. 
 
RPT 0.00003 µmol/hr Scaled from Gentry et. al. 
 
SPT 0.0005 µmol/hr Scaled from Gentry et. al. 
 
SPT Thigh 0.00002 µmol/hr Scaled from Gentry et. al. 
 
Venous 0.0001 µmol/hr Gentry et. al. 
Initial Concentration 
   
 
Arterial 0.001212 µmol Gentry et. al. 
 
Brain 0.04928 µmol Gentry et. al. 
 
Diaphragm 0.000909 µmol Gentry et. al. 
 
Kidney 0.000104 µmol Gentry et. al. 
 
Liver 0.002424 µmol Gentry et. al. 
 
RPT 0.008314 µmol Gentry et. al. 
 
SPT 0.222196 µmol Gentry et. al. 
 
SPT Thigh 0.011708 µmol Gentry et. al. 
 
Venous 0.003454 µmol Gentry et. al. 
Degradation Constant 
   
 
Arterial 0.082508251 hr-1 Calculated 
 
Brain 0.000405844 hr-1 Calculated 
 
Diaphragm 0.00330033 hr-1 Calculated 
 
Kidney 0.038461538 hr-1 Calculated 
 
Liver 0.01650165 hr-1 Calculated 
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RPT 0.003603837 hr-1 Calculated 
 
SPT 0.002250266 hr-1 Calculated 
 
SPT Thigh 0.001708234 hr-1 Calculated 
 
Venous 0.02895194 hr-1 Calculated 
     Butyrylcholinesterase 
   Molecular Weight 83,000 mg/mmol Assumed 
Synthesis Rate 
   
 
Arterial 0.0001 µmol/hr Gentry et. al. 
 
Brain 0.00002 µmol/hr Scaled from Gentry et. al. 
 
Diaphragm 0.000003 µmol/hr Scaled from Gentry et. al. 
 
Kidney 0.000004 µmol/hr Scaled from Gentry et. al. 
 
Liver 0.00004 µmol/hr Scaled from Gentry et. al. 
 
RPT 0.00003 µmol/hr Scaled from Gentry et. al. 
 
SPT 0.0005 µmol/hr Scaled from Gentry et. al. 
 
SPT Thigh 0.00002 µmol/hr Scaled from Gentry et. al. 
 
Venous 0.0001 µmol/hr Gentry et. al. 
Initial Concentration 
   
 
Arterial 0.00606 µmol Gentry et. al. 
 
Brain 0.016859 µmol Gentry et. al. 
 
Diaphragm 0.002 µmol Gentry et. al. 
 
Kidney 0.000782 µmol Gentry et. al. 
 
Liver 0.019392 µmol Gentry et. al. 
 
RPT 0.006236 µmol Gentry et. al. 
 
SPT 0.190454 µmol Gentry et. al. 
 
SPT Thigh 0.010035 µmol Gentry et. al. 
 
Venous 0.017271 µmol Gentry et. al. 
Degradation Constant 
   
 
Arterial 0.01650165 hr-1 Calculated 
 
Brain 0.00118631 hr-1 Calculated 
 
Diaphragm 0.0015 hr-1 Calculated 
 
Kidney 0.00511509 hr-1 Calculated 
 
Liver 0.002062706 hr-1 Calculated 
 
RPT 0.004810776 hr-1 Calculated 
 
SPT 0.002625306 hr-1 Calculated 
 
SPT Thigh 0.001993024 hr-1 Calculated 
 
Venous 0.005790053 hr-1 Calculated 
     Carboxylesterase 
   Molecular Weight 100,000 mg/mmol Assumed 
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Synthesis Rate 
   
 
Arterial 0.0001 µmol/hr Gentry et. al. 
 
Brain 0.00002 µmol/hr Scaled from Gentry et. al. 
 
Diaphragm 0.000003 µmol/hr Scaled from Gentry et. al. 
 
Kidney 0.000004 µmol/hr Scaled from Gentry et. al. 
 
Liver 0.00004 µmol/hr Scaled from Gentry et. al. 
 
RPT 0.00003 µmol/hr Scaled from Gentry et. al. 
 
SPT 0.0005 µmol/hr Scaled from Gentry et. al. 
 
SPT Thigh 0.00002 µmol/hr Scaled from Gentry et. al. 
 
Venous 0.0001 µmol/hr Gentry et. al. 
Initial Concentration 
   
 
Arterial 5.0904 µmol Gentry et. al. 
 
Brain 0.778104 µmol Gentry et. al. 
 
Diaphragm 0.52722 µmol Gentry et. al. 
 
Kidney 4.29957 µmol Gentry et. al. 
 
Liver 110.292 µmol Gentry et. al. 
 
RPT 442.73754 µmol Gentry et. al. 
 
SPT 73.007244 µmol Gentry et. al. 
 
SPT Thigh 3.846888 µmol Gentry et. al. 
 
Venous 14.50764 µmol Gentry et. al. 
Degradation Constant 
   
 
Arterial 1.96448E-05 hr-1 Calculated 
 
Brain 2.57035E-05 hr-1 Calculated 
 
Diaphragm 5.69022E-06 hr-1 Calculated 
 
Kidney 9.3032E-07 hr-1 Calculated 
 
Liver 3.6267E-07 hr-1 Calculated 
 
RPT 6.776E-08 hr-1 Calculated 
 
SPT 6.84886E-06 hr-1 Calculated 
 
SPT Thigh 0.000005199 hr-1 Calculated 
 
Venous 6.89291E-06 hr-1 Calculated 
     Acetylcholine 
   Molecular Weight 146 mg/mmol Calculated 
Activation Rate Constants 
   
 
Brain 0.00719488 mg/hr Calculated 
 
Diaphragm 0.000132714 mg/hr Calculated 
 
Kidney 0.000015184 mg/hr Calculated 
 
Liver 0.000353904 mg/hr Calculated 
 
RPT 0.001213844 mg/hr Calculated 
 
SPT 0.032440616 mg/hr Calculated 
  
69 
 
 
SPT Thigh 0.001709368 mg/hr Calculated 
     Reaction rate coefficients 
   AChE 
   
 
Ka 0.1386 hr-1 Assumed 
 
Ki 220000 mmol-1 hr-1 Assumed 
 
Kr 100 mmol-1 hr-1 Assumed 
 
Ks 1 hr-1 Assumed 
BuChE 
   
 
Ka 0.054 hr-1 Assumed 
 
Ki 110000 mmol-1 hr-1 Assumed 
 
Kr 300 mmol-1 hr-1 Assumed 
 
Ks 1 hr-1 Assumed 
CaE 
   
 
Ka 0 hr-1 Assumed 
 
Ki 110000 mmol-1 hr-1 Assumed 
 
Kr 300 mmol-1 hr-1 Assumed 
 
Ks 1 hr-1 Assumed 
K Ach-AChE 20292.23826 hr-1 Assumed 
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